Skip to content
Altius – Lifestyle
Author:
Xilio Therapeutics, Inc.
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
March 17, 2026
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
March 12, 2026
←
Previous Page
1
2